A one-year prospective study of the safety, tolerability and pharmacokinetics of the highest available dose of paliperidone palmitate in patients with schizophrenia

Risperidone long-acting injection: a review of its long term safety and efficacy

(2011) Michael Rainer   Neuropsychiatric Disease and Treatment

Efficacy and safety of paliperidone palmitate in adult patients with acutely symptomatic schizophrenia: a randomized, double-blind, placebo-controlled, dose-response study

(2010) Srihari Gopal et al.   INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY

A Randomized, Placebo-Controlled Study to Assess the Efficacy and Safety of 3 Doses of Paliperidone Palmitate in Adults With Acutely Exacerbated Schizophrenia

(2010) Gahan J. Pandina et al.   JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY

A Controlled, Evidence-Based Trial of Paliperidone Palmitate, A Long-Acting Injectable Antipsychotic, in Schizophrenia

(2010) Henry A Nasrallah et al.   NEUROPSYCHOPHARMACOLOGY

Population Pharmacokinetics of Intramuscular Paliperidone Palmitate in Patients with Schizophrenia

(2009) Mahesh N. Samtani et al.   CLINICAL PHARMACOKINETICS

Practical guidance for dosing and switching paliperidone palmitate treatment in patients with schizophrenia

(2009) S. Gopal et al.   CURRENT MEDICAL RESEARCH AND OPINION

Long-term outcomes in patients with schizophrenia treated with risperidone long-acting injection or oral antipsychotics in Spain: Results from the electronic Schizophrenia Treatment Adherence Registry (e-STAR)

(2009) J.M. Olivares et al.   EUROPEAN PSYCHIATRY

Paliperidone palmitate, a potential long-acting treatment for patients with schizophrenia. Results of a randomized, double-blind, placebo-controlled efficacy and safety study

(2009) Michelle Kramer et al.   INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY

Safety and tolerability of deltoid and gluteal injections of paliperidone palmitate in schizophrenia

(2009) David Hough et al.   PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY

Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: A randomized, double-blind, placebo-controlled study

(2009) David Hough et al.   SCHIZOPHRENIA RESEARCH